SCM
ITCI

SCS Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

SCS Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-72,743
Closed -$9.6M – 567
2025
Q1 		$9.6M Buy
+72,743
New +$9.07M 0.12% 89

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SCS Capital Management's ITCI Position: Q2 2025 in Review

SCS Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 72,743 shares — an estimated $9.6M sold.

SCS Capital Management first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $9.6M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • SCS Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • SCS Capital Management sold 72,743 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $9.6M.
  • SCS Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • SCS Capital Management's Intra-Cellular Therapies Inc. position peaked at $9.6M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on SCS Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.